| Identification | Back Directory | [Name]
Carbamic acid, N-[(1S)-1-[[(2S)-2-[5-[4-[5-[2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]-1H-imidazol-5-yl]-2-benzofuranyl]phenyl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-, methyl ester | [CAS]
1246470-32-5 | [Synonyms]
Carbamic acid, N-[(1S)-1-[[(2S)-2-[5-[4-[5-[2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]-1H-imidazol-5-yl]-2-benzofuranyl]phenyl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-, methyl ester | [Molecular Formula]
C42H50N8O7 | [MOL File]
1246470-32-5.mol | [Molecular Weight]
778.9 |
| Hazard Information | Back Directory | [Description]
MK-4882 is a potent HCV NS5A inhibitor. | [Uses]
MK-4882 is an HCV NS5A inhibitor with activity in reducing viral load in a chimpanzee model of HCV infection, but with issues of viral breakthrough, prompting the development of compounds with greater potency against more genotypes and NS5A resistance mutations. | [References]
[1] Discovery of potent macrocyclic HCV NS5A inhibitors DOI:10.1016/j.bmcl.2016.05.042
[2] Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity
[3] Discovery and development of hepatitis C virus NS5A replication complex inhibitors |
|
|